Close Menu

NEW YORK – Strata Oncology said on Wednesday that it has entered into a partnership with Kansas City, Missouri-based BioMed Valley Discoveries to identify and enroll for a Phase II study of BioMed's investigational agent ulixertinib.

The Phase II clinical trial will evaluate the efficacy of ulixertinib, a first-in-class small-molecule ERK1/2 inhibitor, in patients with advanced cancers harboring mutations that result in aberrant MAPK pathway signaling.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.